Guardant Health sues rival Natera over cancer-testing trade secrets
Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...
Guardant accuses Natera of poaching employees, stealing trade secrets
The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...
Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...
lifesciencesipreview1d
Natera loses $96m jury win as judge invalidates DNA test patents
Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...
Hosted on MSN1mon
Canaccord maintains Guardant Health stock Buy rating and $42 target
T he analyst from Canaccord Genuity noted Guardant Health (NASDAQ:GH)'s extensive experience in blood-based cancer detection as a competitive advantage, even as Natera (NASDAQ:NTRA) continues to ...
Reuters1y
Natera Inc
Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade secrets related to cancer-detection blood tests. Guardant Health sues ...
Guardant Health price target raised to $50 from $34 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...
Guardant Health price target raised to $52 from $47 at Scotiabank
Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health ...
Yahoo Finance3mon
Natera, Inc. (NTRA)
Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. AUSTIN, Texas, January 17, 2025--Natera, Inc. (NASDAQ ...